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BACKGROUND: In research studies, accurate information of cancer diagnosis is crucial. In women with breast cancer (BC), we compare
cancer registration (CR) in England/Wales and self-reporting with independent confirmation.
METHODS: In the UK Collaborative Trial of Ovarian Cancer Screening, notification of BC diagnosed between randomisation and
31 December 2009 was obtained through (1) CR (17 October 2011) and (2) self-reporting using postal-questionnaire. Breast cancer
was confirmed using a detailed questionnaire (BC questionnaire BCQ) completed by the treating clinician (gold standard). Apparent
sensitivity and positive-predictive value of CR/self-reporting vs BCQ were calculated.
RESULTS: Of 1065 women with possible BC notification, diagnosis was confirmed in 932 (87.5%). A total of 3.1% (28 out of 918) of BC
CR and 12.4% (128 out of 1032) of women with self-reported BC only had in-situ carcinoma on BCQ. Another 4.6% (43 out of 932)
of BCQ-confirmed cancer did not have a BC registration, and 3.6% (34 out of 932) did not self-report BC. Apparent sensitivity of
CR and self-reporting vs BCQ were 95.4 and 96.4%, respectively. Positive-predictive value of self-reporting (87.1%) was significantly
lower than that of CR (96.8%). Women agedo65 were more likely to over report in-situ carcinoma as BC. Overall, 73 (6.8%)
women would have been misclassified/missed if CR, and 167 (15.6%) if self-reporting data alone was used.
CONCLUSION: This study confirms the reliability of BC registration in England/Wales and highlights the fact that 1 in 10 women self-
reporting BC might only have in-situ breast carcinoma.
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National cancer registries collect comprehensive cancer informa-
tion for the whole population, which enables documentation of
historical trends in cancer incidence/survival. In the UK, there are
three registries covering England and Wales, Scotland and
Northern Ireland, respectively. New diagnosis of cancer occurring
in the populations is acquired from a variety of sources, and
checked for validity and completeness through a complex process
of clinical data linkage and consolidation. Overall, the data on
cancer registrations (CRs) has been shown for the most part to be
reliable (Gulliford et al, 1993). Few major errors in the
International Classification of Diseases (ICD) coding have been
reported (Lapham and Waugh, 1992), with the data regarding
cancer stage, grade and date of treatment being less consistent.
Brewster et al (2002) concluded that even though the quality of
cancer registry data may be good, improvements are needed in
standardising the recording of information by clinicians.
Cancer registries are often used in research studies where cancer
diagnosis and mortality are the key outcome measures or eligibility
criteria. To compensate for delays or lack of completeness in CR,
researchers often use additional sources such as self-reporting
using questionnaires or assessment of medical records.
Questionnaires are regarded as the most cost-effective way in
obtaining these data (Abraham et al, 2009). However, the validity
of self-reporting seems dependent on the site of cancer, with breast
cancer (BC) having the best sensitivity (Paganini-Hill and Chao,
1993; Schrijvers et al, 1994; Bergmann et al, 1998; Desai et al, 2001;
Parikh-Patel et al, 2003; Manjer et al, 2004; Dominguez et al, 2007;
Brewster and Stockton, 2008), and on a variety of factors such as
age, education, previous family history and race (Schrijvers et al,
1994; Bergmann et al, 1998; Desai et al, 2001; Parikh-Patel et al,
2003; Manjer et al, 2004; Dominguez et al, 2007; Abraham et al,
2009). The abstraction of clinical information from medical reports
obtained directly from the clinicians treating the patient is the
most accurate means of collecting cancer data (Schootman et al,
2005). However, it can be extremely time-consuming and
expensive, especially across multiple hospitals (Phillips et al,
2005).
Most reports on accuracy of cancer data have compared two
information sources (self-reported data, cancer registry records or
medical notes). Only two studies have looked at all three sources
of cancer data. Bergmann et al (1998) compared accuracy of
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self-reported cancer diagnoses with population-based cancer
registry data and investigated self-reports of cancer that were not
confirmed by the registries using medical records. In a more recent
large study of women attending the US mammography facilities
between 1996 and 2006, Abraham et al (2009) compared self-
reporting with data from cancer registries and pathology
databases. Both studies were in the US populations, and there is
no data we are aware of from England that has explored all three
sources together.
In the UK Collaborative Trial of Ovarian Cancer Screening
(UKCTOCS), all women were flagged through the cancer registry
and were sent questionnaires that included specific questions
regarding BC. Clinicians were contacted to confirm any BC
notification. Given the wide implications of reliability of cancer
diagnosis, we compare each (registration and self-reporting of BC)
with histopathological confirmation by the clinician. In addition,
we elucidate possible causes of errors and discrepancies;
investigate the effect of time on BC registration delays, and
examine the association between BC self-reporting and previously
described factors such as age, education and family history of BC.
METHODS
Subjects
The UKCTOCS is a multi-centre, randomised controlled trial for
ovarian cancer screening in postmenopausal women from the
general population in England, Wales and Northern Ireland
(Menon et al, 2008). A total of 189 063 women were recruited
into the trial from England and Wales between April 2001 and
September 2005.
BC cases
The BC cases were women residing in England and Wales, who
were diagnosed with possible invasive BC in the period between
randomisation and December 2009. Breast cancers diagnosed
after women had completed their follow-up questionnaire were
excluded. Women recruited from Northern Ireland were excluded
as data from the Northern Ireland cancer registry was incomplete
at start of study.
Identification of possible BC cases
Cancer registry All participants are being followed up through a
‘flagging study’ with the National Hospital Service (NHS)
Information Centre for Health and Social Care (formerly Office
for National Statistics) in England and Wales. The linkage was
performed using the NHS number, the surname, the address and
date of birth of the volunteer. The UKCTOCS co-ordinating centre
receives electronic data that includes cancer registration on each
subject from the NHS Information Centre for Health and Social
Care every 6 months. The relevant ICD codes for malignant
neoplasm of breast used for this analysis were C50*- ICD-Code 10
and 174*- ICD-Code 9. Women with ICD codes for benign
conditions or in-situ carcinomas of the breast were not included.
When women had two cancer registry records with different dates
of diagnosis, the earliest date of diagnosis was used.
Self-report through the UKCTOCS follow-up questionnaire The
UKCTOCS protocol included an 11-item follow-up questionnaire
(FUQ) sent 3–5 years after randomisation. It included a specific
question related to BC diagnosis since randomisation (Figure 1).
The overall UKCTOCS FUQ response rate was 71.2% (134 602 out
of 189 063). For the self-reported BCs, it was not possible to
distinguish between a recurrence and second primary.
Report from the UKCTOCS trial centres A few notifications were
also received directly from the participating trial centres of
women, identified as a result of ovarian cancer screening using
annual serum CA125 in the trial.
Confirmation of BC diagnosis
The treating physician of all women who were identified to have
developed BC after randomisation, and who had provided contact
details of their clinician were sent BC Questionnaire (BCQ,
Supplementary Figure 1). This 15-item BCQ included questions
on diagnosis, histopathology and treatment, and was used to
confirm diagnosis.
Data analysis
Performance characteristics All women for whom it was possible
to obtain data from the three sources were included in the analysis.
If both BC and in-situ carcinoma of breast was reported in the
same woman, BC diagnosis was used for comparisons. Analysis
was undertaken comparing cancer registry and self-reported data
with the gold standard-BCQ. Misclassifications were identified for
cancer registry and self-reporting individually. The true-positive,
false-positive, false-negative and true-negative (TN) were assessed,
and the apparent sensitivity and positive-predictive value (PPV) of
each data source was calculated as shown in Figure 2. Apparent
sensitivity was used, as it was not possible to contact physicians of
Since joining UKCTOCS, have you been diagnosed with any cancer?
please tell us about this(ese) cancer(s)
Ovarian cancer Bowel/colorectal cancer Lung cancer
Vulval/vaginal cancer
BCC/rodent/skin cancer
Other cancer
Gastric/stomach cancer
Pancreatic cancer
Kidney cancer
Breast cancer
Cervical cancer
Endometrial/uterus/womb cancer
I have not been diagnosed with any cancers
Type of cancer:
Year of operation: Hospital no.:
Hospital at which operation took place:
Name of consultant:
Figure 1 Question on BC diagnosis included in the follow-up questionnaire sent to the women participating in the trial.
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all women to identify those with BC, who had not self-reported and
had no CR (TN). Fisher’s test was used to compare sensitivities and
PPVs of cancer registry and self-report. Combining cancer registry
and self-reported data was explored using the following rules: (a)
BC case is correctly reported if both sources concurred for BC
diagnosis and (b) BC case is correctly reported if either source
(cancer registry or self-report) reported BC diagnosis.
CR delays The effect of time on cancer-registration delays was
assessed by looking at the completeness of relevant CRs according
to the year of diagnosis and time from diagnosis to cancer-registry
notification.
Performance characteristics in relation to baseline characteristics
The baseline characteristics of the study women were calculated
using descriptive statistics. The following factors were analysed to
investigate whether self-reporting is dependent on them: ethnicity
(White, Black, others) age at follow-up, BC family history (no and
yes, including first- and second-degree relatives), education (high:
college/university degree or nursing/teaching qualification, low: A/
O-level, vocational qualifications such as clerical and commercial/
or equivalent, other: none of the above), smoking (have you ever
been a smoker – yes, no), alcohol consumption each week (units
per week are provided), pill use (yes, no), sterilisation (yes, no),
hysterectomy (yes, no) and HRT use at recruitment (yes, no).
Apparent sensitivity was modelled using logistic regression, with
the above characteristics as the independent variables, and using
only those cases where the BCQ confirmed BC. All four variables
were suitably categorised before modelling, and from the
regression, the respective odds ratio and significance levels were
estimated, given the other variables’ presence in the equation.
Positive-predictive value was also modelled in exactly the same
way. Analysis was carried out using a computer-assisted pro-
gramme SPSS version 12.0.1 (Chicago, IL, USA).
Apparent sensitivity = TP / TP + FN
PPV = TP / TP + FP
+
TNFN
FPTP
+ –
–
Gold standard
BCQ/histopathology report
Cancer
registry/FUQ
Figure 2 Description of performance characteristics used for data
analysis. Calculation of apparent sensitivity and positive predictive value
(PPV) for cancer registry and follow-up questionnaire (FUQ) data using the
BC questionnaire (BCQ)/ histopathology report as the gold standard.
Abbreviations: FN¼ false negative; FP¼ false positive; TN¼ true negative;
TP¼ true positive.
4329 Women with breast cancer notifications between randomisation and 17 October 2011
Cancer registry only, n =2250
Self-reporting through FUQ, n =456
Cancer registry and self-reporting through FUQ, n =1623
Women for whom a BCQ was sent to the treating clinician
n =1521 (83.5%)
Women for whom BCQs were returned
n =1085 (71.3%)
Women with complete data on cancer registry, FUQ, BCQ who were
 included into the final analysis Final n =1065
Exclusion criteria:
Women diagnosed between 2010 and 2011, n =473
Women who did not return FUQ, n =968
Women who completed the FUQ before their breast cancer 
diagnosis, n =1022
Women eligible for current study
n =1866
Women who did not provide the contact details 
of the treating clinician, n =309
Women for whom complete histological information 
was missing, n =20
Women for whom a BCQ was not provided, n =436
Figure 3 Diagram showing how the study subjects were identified. Abbreviations: BCQ¼ BC questionnaire; FUQ¼ follow-up questionnaire.
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RESULTS
In the trial centre, 4329 notifications of possible BC diagnoses were
received between April 2001 and October 2011. A total of 2463
women were excluded from the study, as they were diagnosed
between 2010 and 2011 (473), completed the FUQ before their BC
diagnosis (1022) or had not returned their FUQ questionnaires
(968). Of the 1866 eligible women, it was possible to obtain a
complete set of data, including self-reporting, CR and clinician
confirmation using BCQ/histopathology for 1065 women
(Figure 3). The baseline characteristics of these women are
detailed in Table 1. Of these 1065 women, BCQ confirmed invasive
BC in 932 (87.6%), in-situ ductal carcinoma of the breast in 126,
in-situ lobular carcinoma of the breast in 2, benign changes in 3,
and no breast pathology in 2. The median age at diagnosis
of the 932 women with BCQ-confirmed BC was 63 years (95%
CI: 62.77–63.53 years).
A total of 918 women had BC registration on 17 October 2011. In
all, 3.1% (28 out of 918) of women with BC registrations had only
evidence of in-situ carcinoma of the breast, and 0.1% (1/918) had
only evidence of benign breast pathology. Of the 932 confirmed
BCs on BCQ, 43 (4.6%) did not have a BC registration,
despite having a confirmed diagnosis a median of 6.8 years
(inter-quartile range: 4.9 years) before the last cancer registry
follow-up (Figure 4A). The apparent sensitivity of cancer registry
was 95.4% (93.4 to 96.2) and PPV was 96.8% (95.3 to 97.8;
Figure 4C).
A total of 1032 women self-reported BC. In all, 12.4% (128 out of
1032) women self-reporting BC only had in-situ carcinoma of the
breast on BCQ; 3.6% (34/932) of women did not report BC
(Figure 4B), despite having a confirmed diagnosis a median of 1.6
years (inter-quartile range: 2.3 years) before completion of FUQ.
The apparent sensitivity of self-reporting on the FUQ was 96.4%
(95.3 to 97.3) and PPV was 87.1% (86.5 to 90.5; Figure 4C).
Out of 932 women with confirmed BC diagnosis on BCQ, both
cancer registry and self-reporting concurred in 819 (87.9%)
women diagnosed with BC. Overall, in the cohort of 1065 women,
73 (6.8%) women would have been misclassified/missed if cancer
registry data alone was used, and 167 (15.6%) if self-reporting data
alone was used. When the rule that BC case is confirmed if either
source (cancer registry or self-reporting through the FUQ)-
reported BC diagnosis was applied, there were 210 women
(19.7%) who would have been misclassified or missed. The rule
that both sources (cancer registry and self-reporting) need to
concur for BC diagnosis gave the lowest rate of misclassifications
with 30 (2.7%) women who would have been falsely identified as
BC cases (Table 2).
Cancer registry delays
We investigated whether delays in cancer registry might account
for the lack of CR on 17 October 2011. Between 2001 and 2002,
there were no women diagnosed with BC with a missing
registration code. The highest percentage of women 30% (12/40)
with no CR were those diagnosed in the year 2008. Only three
women diagnosed in 2009 were included in this analysis, and
all of them had a CR (Figure 5).
Table 1 Distribution and frequency of sociodemographic characteristics
of all the study subjects (N¼ 1065)
Distribution
Characteristics No of women %
Age at follow-up
465 523 49.1
o65 536 50.3
Missing 6 0.6
Age at diagnosisa
465 538 57.3
o65 393 42.2
Missing 1 0.5
Ethnicity
White 1046 98.2
Black 7 0.7
Other 7 0.7
Missing 5 0.5
Education
Other 281 26.4
Low 385 36.1
High 352 33.1
Missing 47 4.4
Alcohol (units per week)
0 205 19
1–30 570 54
4–70 261 25
Missing 29 3
Smoking
Yes 469 44
Breast cancer family history at
recruitment
Yes 290 27.2
Pill use
Yes 646 60.7
Sterilisation
Yes 180 16.9
Hysterectomy
Yes 185 17.4
HRT use at recruitment
Yes 295 27.7
Year of diagnosisa
2001 2 0.21
2002 32 3.43
2003 89 9.55
2004 187 20.1
2005 250 26.8
2006 230 24.7
2007 99 10.6
2008 40 4.29
2009 2 0.21
Not known 1 0.11
aFor the 932 women with confirmed breast cancer diagnosis.
Performance characteristics
Cancer registry
BCQ (Gold standard)
% Apparent sensitivity (95% CI) 0.21
% PPV (95% CI) <0.0001
34
+
+
–
–
Gold standard
BCQ
Self-
reporting
0
898
43 
+
+ –
–
Gold standard
BCQ
Cancer
registry
105
888 29 133
96.4 (94.9 to 97.3)95.4 (93.4 to 96.2)
87.1 (86.5 to 90.5)96.8 (95.3 to 97.8)
P -valueSelf-reporting
Figure 4 Performance characteristics for cancer registry and UKCTOCS
follow-up questionnaire (FUQ). Numbers of true positives (TP), false
positives (FP), false negatives (FN) and true positives (TP) for BC cases
identified within UKCTOCS. Comparison with gold standard (BQC/
histopathology) of (A) Cancer Registry and (B) self-reporting through
FUQ. (C) Calculation of sensitivity and positive predictive value (PPV).
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Apparent sensitivity and PPV of BC by women
self-reporting based on characteristics
Age at completion of FUQ was a significant determinant for PPV
but not for apparent sensitivity, with women o65 in comparison
with women 465 over-reporting their BC diagnosis. All the
other factors investigated were not shown to be associated with
self-reporting (Table 3).
DISCUSSION
This is the first study in England and Wales to examine the
performance characteristics of both self-reporting and CR for BC
against the gold standard of confirmation by the treating
physician. It confirms the reliability of BC registration in England
and Wales. Our data also suggests that although self-reporting
using postal questionnaires is a good source of cancer data, 1 in
10 women self-reporting BC may only have in-situ carcinoma.
This finding highlights the need for better patient information
regarding the differences between in-situ carcinomas and invasive
disease. It also points out that on surveys when women are
questioned about their BC diagnoses, a separate question on
in-situ carcinomas should be included.
One of the key strengths of this study is that CR data was
available for 99.99% of the cohort. Eight women refused consent to
flagging. We were able to ‘flag’ all women recruited from England
and Wales who gave consent with the NHS Information Centre for
Health and Social Care. This was due to having accurate NHS
numbers as a result of electronic transfer of the information from
Primary Care age–sex registers (Menon et al, 2008). Additional
strengths include over 70% of women in the cohort completing
the self-reporting questionnaire (FUQ) and confirmation of BC
diagnosis by contacting the consultants responsible for treatment
with high response rates (70%). There is a time lag between
diagnosis and CR, and this was taken into account by including CR
records till October 2011, but limiting the analysis to cancers
diagnosed till December 2009. A limitation was that at the time of
analysis, in women with a BC notification where the woman had
not provided the name of the breast specialist, the GP had not been
contacted for confirmation. This analysis does not distinguish
between women who have two primary cancers or a primary
cancer with recurrence. It has been done per woman and not per
primary BC diagnosis. Additionally, it was not possible to contact
the GP of all the 189 063 women in the cohort to identify any
women with BC, who had neither self-reported nor had a CR.
Hence, we are unable to estimate the number of cases with no CR
where women too had not self-reported. Recent data suggests this
effect may be small. On linking CR with information from the
Hospital Episode Statistics (HES) database for BC patients in
England for the period 2001–2007, Moller et al (2011) found that
HES data only added 2.0% to the number of BC registrations.
We have recently obtained HES data for the women in the cohort
from England and hope to explore this in due course.
Cancer registry has high sensitivity (95.4%) and PPV (96.8%),
for BC and researchers can rely on this data. The apparent
sensitivity reported in this study is comparable to the most recent
report of 98.0% by Brewster et al (2008) investigating the Scottish
cancer registry. The rates are similar to Gathani et al (2005) who
reported a sensitivity of 96% for BC diagnosis on comparing
cancer registry data with the NHS Breast Screening Programme in
the largest study so far in England, including more than 5000 BC
cases. Overall, though there are few studies in England on
validation of CR data and most of them include only a small
number of BC cases, the data suggests that sensitivity of cancer
registry for BC has improved over the last decades (from 72% in
1987 to 95% in this report), and it is likely that further
improvements in the recording of cancer data by the regional
cancer registries will result in complete data as similar to the
Scandinavian countries (Jensen et al, 2002).
Sensitivity of self-reporting is 96.4% with significantly lower
PPV (87.1%) when compared with that of cancer registry. The
observed high sensitivity of self-reporting for BC diagnosis is
comparable to that reported in the US studies by Parikh-Patel et al
(2003; 98.1%) and Abraham et al (2009; 96.9%). A key finding is
that almost 12% of women self-reporting BC were only found to
have in-situ carcinoma of the breast and this was significantly
Table 2 Identified misclassifications/errors on comparison to BCQ and their causes. The error is dependent on the data source and how it is interpreted
Data source and interpretation
Cause of misclassification
Self-
report
Cancer
registry
Cancer registry and
self-reporting
(both need to concur
for breast cancer diagnosis)
Cancer registry and
self-reporting
(breast cancer diagnosis, if
either report the diagnosis)
In-situ carcinoma of the breast or benign condition or no cancer
misclassified as breast cancer or other cancer
133 30 29 133
Breast cancer misclassified as in-situ carcinoma of the breast or
benign condition or other cancer
0 14a 0 14a
Breast cancer not reported/registered 34 29 1 63
Total number (%) of errors (either misclassified or
not reported/registered)
167 73 30 210
aA total of 11 women (1.1%) with in-situ ductal carcinoma of the breast registration of whom 2 had a second registration for another cancer and 3 (0.3%) other cancer alone.
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Figure 5 Proportion of women with confirmed BC without a
registration code per year, based on the last cancer registry follow-up
(17 October 2011).
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more in women aged o65. On reviewing the literature, it is clear
that although we have considered in-situ breast carcinoma, which
was self-reported as BC under false positives (over-reporting),
Abrahams et al (2009) in their analysis have included this group
under true positives. It suggests that while a diagnosis of in-situ
carcinoma may be a difficult concept for the women, researchers
too are not in agreement on how it should be grouped.
A total of 3.6% of women did not report BC despite having a
confirmed diagnosis (under-reporting). A variety of factors have
been suggested to affect BC self-reporting, including age, sex,
education and family history of BC (Bergmann et al, 1998;
Abraham et al, 2009). The only factor in our analysis that was
associated with self-reporting was age. Although age at completion
of FUQ did not make any difference to under-reporting (apparent
sensitivity), it was significantly correlated with over-reporting
(PPV). Younger women were more likely to over-report in-situ
breast carcinoma as BC compared with older respondents.
Previous studies have shown age to affect both under- and
over-reporting (Schrijvers et al, 1994; Bergmann et al, 1998;
Parikh-Patel et al, 2003; Manjer et al, 2004; Dominguez et al, 2007).
In addition, it has been suggested that women who are less
educated are more likely to over-report cancer diagnosis
(Schrijvers et al, 1994; Bergmann et al, 1998; Desai et al, 2001;
Abraham et al, 2009) and those with a family history of BC are
better responders when asked about their BC diagnosis (Abraham
et al, 2009). We found no significant effect on reporting of either
education or family history of BC. In studies that rely entirely on
cancer data self-reported by participants, factors that have been
shown to affect reporting may need to be taken into account.
Studies often use cancer registry or self-reported data. If only
one source was to be used, then in England and Wales, cancer
registry would be more complete with only 6.8% of women with BC
missed/misclassified compared with 15.6% using self-reported
data alone. In studies or trials where both sources are available, the
lowest rate of misclassification of BC (2.7%) would be obtained by
applying the rule that both sources need to concur for BC
diagnosis. Nearly one in five women with BC notification would be
missed/misclassified if the rule used was that BC is confirmed if
reported on either source (cancer registry or self-reporting).
In conclusion, this study confirms that BC registration in
England and Wales is highly reliable. Self-reporting, using postal
questionnaires is another good source of cancer data. However,
one in ten women self-reporting BC might only have
in-situ breast carcinoma and women agedo65 are more likely to
over report. It suggests the need for standardisation of information
that patients receive.
Table 3 Characteristics of the study women with known data as determinants of apparent sensitivity and PPV. The respective OR and significance levels
were estimated
Variable
Apparent
sensitivity N OR 95% CI
P-
value PPV N OR 95% CI P-value
Ethnicity
White 98.5 872 1 87.2 985 1
Black 5 7
Other 7 (Not
measurable)
7 (Not
measurable)
Age groups (years)
50–64 1 85.2 499 1
65–80 0.7 0.6 89.3 505 1.6 1.1–2.5 0.02
Education
Other 98.3 239 1 84.8 277 1
Low 99.1 338 1.7 0.3–8.2 0.5 87.7 382 1.4 0.9–2.2 0.2
High 98.1 312 0.2 0.2–2.7 0.6 88.7 345 1.5 0.9–2.4 0.1
Breast cancer family history
No 98.8 645 1 86.8 734 1
Yes 98 244 0.6 0.2–2.5 0.4 88.6 270 1.6 0.8–1.9 0.3
Alcohol
None 98.3 178 1 85.4 205 1
1–2 Units per week 97.7 352 0.7 0.2–2.8 0.6 88.7 388 1.3 0.8–2.2 0.2
X3 Units per week 99.4 359 3.6 0.6–23.3 0.2 86.9 411 1.1 0.6–1.8 0.7
Smoking
No 98.8 490 1 87.1 556 1
Yes 98.2 399 0.8 0.2–2.0 0.4 87.5 448 1.1 0.8–1.6 0.6
Oral contraceptive pill
No 98.6 351 1 87.1 394 1
Yes 98.5 538 1.1 0.3–3.8 0.9 87.5 610 0.9 0.6–1.5 0.9
Sterilisation
No 98.8 735 1 87 832 1
Yes 98.2 154 0.6 0.2–4.0 0.8 88.4 172 1.2 0.7–2.1 0.4
Hysterectomy
No 98.8 732 1 87 831 1
Yes 97.5 157 0.5 0.1–1.7 0.2 88.5 173 1.2 0.7–1.9 0.6
HRT use
No 98.8 635 1 86.9 722 1
Yes 97.5 254 0.6 0.2–2.0 0.4 88.3 282 1.2 0.8–1.9 0.4
TOTAL 98.5 87.3
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